Bimekizumab Well Tolerated for Patients With Moderate to Severe Plaque Psoriasis
For patients with moderate to severe plaque psoriasis, bimekizumab was well tolerated, according to a study published in JAMA Dermatology. Kenneth B. Gordon, MD, and colleagues evaluated the 2-year safety profile of bimekizumab...
Read More